ArticleChest2026
Role of Radiographic Fibrosis Extent in Identifying Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTreatment selection in chronic hypersensitivity pneumonitis (HP) remains empiric because of a lack of randomized trial data. Although radiographic fibrosis extent often is used to inform treatment decisions, its usefulness as a theragnostic marker for immunomodulatory therapy is unknown. RESEARCH QUESTION: Is visual fibrosis extent on high-resolution CT (HRCT) imaging associated with differential pulmonary function response to immunomodulation in chronic HP? STUDY DESIGN AND
methodsThis retrospective cohort study included 108 patients with HP from 2 interstitial lung disease (ILD) referral centers who received ≥ 3 months of immunomodulatory therapy (prednisone, azathioprine, mycophenolate mofetil, and rituximab) and had undergone pulmonary function testing and HRCT imaging before and after treatment. Fibrosis extent was classified as ≥ 10% or < 10% based on masked radiologist reads. Linear spline mixed-effects models were used to estimate FVC and diffusion capacity of the lungs for carbon monoxide (Dlco) % predicted trajectory before and after immunomodulation, with patients serving as their own controls. The primary analysis evaluated whether fibrosis extent modified the association between immunomodulation and lung function trajectory.
resultsOverall, immunomodulation was associated with a modest FVC improvement at 12 months (+2.63%; 95% CI, 0.72-4.54; P < .01). Among patients with < 10% fibrosis, immunomodulation was associated with improvements in both FVC (+5.83%; P < .01) and Dlco (+13.9%; P < .01). In contrast, no improvement in FVC (+0.81%; P = .42) or Dlco (-4.3%; P = .17) was observed in patients with ≥ 10% fibrosis at 12 months. Baseline demographics, smoking history, and antigen identification status were similar between fibrosis groups.
interpretationThe results of this study indicate that visual fibrosis extent is associated with differential pulmonary function response to immunomodulatory therapy in chronic HP. Patients with limited fibrosis demonstrated improved pulmonary function compared with those with greater radiographic fibrosis. These findings may support the use of fibrosis extent as a clinical tool for treatment stratification and highlight the need for prospective trials to validate radiographic markers in guiding HP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.